Category: Candy, confectionary, snacks and sweeteners
What to do: Do not consume recalled products to which you are allergic or sensitive.
Audience: General public
Recall class: Class 1
Affected products
Brand
Product
Size
UPC
Codes
Crave Stevia
Almond All Natural Chocolate
80 g
85 g
8 84063 00088 3
All codes where milk is not declared on the label
Crave Stevia
Dark All Natural Chocolate
80 g
85 g
8 84063 00085 2
All codes where milk is not declared on the label
Crave Stevia
Mint All Natural Chocolate
80 g
85 g
8 84063 00084 5
All codes where milk is not declared on the label
Crave Stevia
Sea Salt All Natural Chocolate
80 g
85 g
8 84063 00083 8
All codes where milk is not declared on the label
Crave Stevia
Sprinkles All Natural Chocolate
80 g
85 g
8 84063 00118 7
All codes where milk is not declared on the label
Crave Stevia
Chocolate Chips
200 g
8 84063 00069 2
All codes where milk is not declared on the label
Issue
The affected products are being recalled from the marketplace because they may contain milk which is not declared on the label.
The recalled products have been sold in British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, Quebec, New Brunswick, and Nova Scotia, and may have been distributed in other provinces and territories. They have also been sold online.
What you should do
Check to see if you have recalled products
Do not consume recalled products to which you are allergic or sensitive as they may cause a serious or life-threatening reaction
Do not serve, use, sell or distribute recalled products
Recalled products should be thrown out or returned to the location where they were purchased
The IAMStm brand, proudly part of the Mars family of brands, announced today the launch of the IAMStm Puppy Hub and Kitten Hub, two online tools featuring expert knowledge and advice for new and soon-to-be pet parents. Each Hub will bring...
Today, TELUS Health announced a collaboration with Nova Scotia Health (NSH) to enable residents of Nova Scotia to access their primary care information through the YourHealthNS app. This health data interoperability initiative marks the first...
The global Digital Healthcare Market, valued at $220.10 billion in 2024, is on a trajectory of rapid expansion, with projections indicating it will soar to $836.10 billion by 2031, growing at a compound annual growth rate (CAGR) of 21% from 2024 to...
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period.
The...
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...